News - Kadcyla

Filter

Current filters:

Kadcyla

Popular Filters

Synthon’s SYD985 may broaden target population of cancer patients

02-04-2014

Dutch generic drugs company Synthon Biopharmaceuticals has released the results of a head-to-head comparative…

KadcylaOncologyPharmaceuticalResearchRocheSYD985Synthon Biopharmaceuticals

Roche’s breast cancer drug Kadcyla debuts in UK

Roche’s breast cancer drug Kadcyla debuts in UK

13-02-2014

Swiss drug major Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) is now available for UK patients…

KadcylaMarkets & MarketingNorthern EuropeOncologyPharmaceuticalRocheUK

Roche’s Kadcyla approved in the EU for advanced HER2-positive breast cancer

Roche’s Kadcyla approved in the EU for advanced HER2-positive breast cancer

20-11-2013

Swiss drug major Roche says that Kadcyla (ado-trastuzumab emtansine or T-DM1), the latest targeted medicine…

EuropeKadcylaOncologyPharmaceuticalRegulationRoche

Japan NHI price listing for Chugai’s Kadcyla delayed

14-11-2013

Japanese drugmaker Chugai Pharmaceutical, which is majority owned by Swiss major Roche, says that the…

Asia-PacificChugai PharmaceuticalKadcylaOncologyPharmaceuticalPricingResearchRoche

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production

14-10-2013

Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

Roche highlights late-stage pipeline beyond cancer

02-10-2013

Swiss drug major Roche has provided an update from its leading late-stage pipeline comprising 10 new…

Gastro-intestinalsKadcylalampalizumabOncologyOphthalmicsPharmaceuticalResearchRoche

Highlights from European Cancer Congress on Kadcyla, Yervoy, Erbitux and Somatuline

30-09-2013

A host of new oncology data was presented at the European Cancer Congress in Amsterdam, the Netherlands,…

Bristol-Myers SquibbErbituxEuropeIpsenKadcylaMerck KGaAOncologyPharmaceuticalResearchRocheSomatulineYervoy

CHMP positive decision for Kadcyla, and approval in Japan

20-09-2013

The cancer drug Kadcyla (trastuzumab emtansine) has today received a positive opinion from the European…

Asia-PacificEuropeImmunoGenKadcylaOncologyPharmaceuticalRegulationRoche

FDA advisory panel backs new indication for Genentech's Perjeta

13-09-2013

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

Roche hopes Kadcyla will replace revenue lost by Herceptin patent expiry

02-08-2013

Swiss drug major Roche (ROG: SIX) could be hit by biosimilar versions of its breakthrough HER2-positive…

EuropeFinancialHerceptinKadcylaOncologyPharmaceuticalRoche

US FDA approves Roche's late-stage breast cancer drug Kadcyla

25-02-2013

The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

Back to top